Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2011, Article ID 952584, 3 pages
http://dx.doi.org/10.1155/2011/952584
Case Report

Cardiovascular Side Effects of Atomoxetine and Its Interactions with Inhibitors of the Cytochrome P450 System

1PGY1, International Scholars Program, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
2PGY3, International Scholars Program, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
3University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA

Received 10 February 2011; Accepted 16 May 2011

Academic Editor: B. Wedi

Copyright © 2011 Pashtoon Murtaza Kasi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Hazell, K. Becker, E. A. Nikkanen et al., “Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder,” Attention Deficit and Hyperactivity Disorders, vol. 1, no. 2, pp. 201–210, 2009. View at Google Scholar
  2. P. M. Wehmeier, A. Schacht, R. Escobar, N. Savill, and V. Harpin, “Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: meta-analysis of five atomoxetine trials,” Child and Adolescent Psychiatry and Mental Health, vol. 4, article no. 30, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Bastiaens, “Effectiveness and tolerability of atomoxetine in a real-world ADHD population: nonrandomized comparison with stimulants,” Psychiatry (Edgmont), vol. 4, no. 12, pp. 44–48, 2007. View at Google Scholar
  4. P. Hammerness, K. McCarthy, E. Mancuso, C. Gendron, and D. Geller, “Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review,” Neuropsychiatric Disease and Treatment, vol. 5, no. 1, pp. 215–226, 2009. View at Google Scholar · View at Scopus
  5. D. Scherer, D. Hassel, R. Bloehs et al., “Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents,” British Journal of Pharmacology, vol. 156, no. 2, pp. 226–236, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Ledbetter, “Atomoxetine: a novel treatment for child and adult ADHD,” Neuropsychiatric Disease and Treatment, vol. 2, no. 4, pp. 455–466, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. “Prescribing Information on Strattera,” Eli Lilly and Company, pp. 1–17, http://pi.lilly.com/us/strattera-pi.pdf.
  8. J. F. Wernicke, D. Faries, D. Girod et al., “Cardiovascular effects of atomoxetine in children, adolescents, and adults,” Drug Safety, vol. 26, no. 10, pp. 729–740, 2003. View at Publisher · View at Google Scholar
  9. J. Barton, “Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder,” Archives of Disease in Childhood, vol. 90, no. 1, pp. i26–i29, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. J. M. Sauer, B. J. Ring, and J. W. Witcher, “Clinical pharmacokinetics of atomoxetine,” Clinical Pharmacokinetics, vol. 44, no. 6, pp. 571–590, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. A. S. Rajesh, G. Bates, and J. G. C. Wright, “Atomoxetine-induced electrocardiogram changes,” Archives of Disease in Childhood, vol. 91, no. 12, pp. 1023–1024, 2006. View at Publisher · View at Google Scholar · View at Scopus